Swedish medical technology company SciBase Holding AB (STO: SCIB) announced on Thursday that it has partnered with dermatology practice Seraly Dermatology in Pittsburgh, Pennsylvania.
Through this partnership SciBase will continue to expand access to the Nevisense test to patients across the US and further its commitment to the early detection of melanoma, when the disease is almost 100% curable.
Seraly Dermatology will integrate various Nevisense systems into its skin cancer detection workflow.
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Sichuan Kelun-Biotech reveals sacituzumab tirumotecan (sac-TMT) clinical studies results
Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial
EDX Medical launches new testicular cancer detection test in UK
Oncolytics Biotech signs share purchase agreement with Alumni Capital
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
MaaT Pharma receives positive DSMB safety recommendation for Phase 2b trial of MaaT033